Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2018 (2018), Article ID 1952685, 8 pages
Research Article

Factors Associated with Outcomes of Percutaneous Transluminal Renal Angioplasty in Patients with Renal Artery Stenosis: A Retrospective Analysis of 50 Consecutive Cases

1Division of Hypertension and Nephrology, Department of Medicine, National Cardiovascular Center, Osaka, Japan
2Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus, Okinawa, Japan
3Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan
4Department of Radiology, National Cardiovascular Center, Osaka, Japan
5Division of Cardiovascular Radiology, Department of Radiology, Iwate Medical University, Iwate, Japan
6Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan
7Diage Kobe Clinic, Hyogo, Japan
8Department of Medical Technology, Teikyo University, Fukuoka Campus, Fukuoka, Japan

Correspondence should be addressed to Tetsutaro Matayoshi

Received 21 September 2017; Accepted 7 December 2017; Published 4 January 2018

Academic Editor: Masayoshi Soma

Copyright © 2018 Tetsutaro Matayoshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The results of recent trials have brought some confusion to the treatment strategy for renal artery stenosis (RAS). To evaluate the applicability of percutaneous transluminal renal angioplasty (PTRA) for RAS, we extracted the factors that may affect the effectiveness of PTRA from cases experienced at a hypertension center. Methods and Results. We retrospectively assessed the blood pressure (BP) lowering effects and renoprotective effects in 50 consecutive patients that had hemodynamically significant RAS and had undergone PTRA and stenting during 2001–2005. Subjects were diagnosed with atherosclerotic RAS (42), fibromuscular dysplasia (6), or Takayasu disease (2). After PTRA, BP significantly lowered from 152.3/80.3 mmHg to 132.6/73.2 mmHg (), but the estimated glomerular filtration rate (eGFR) did not change significantly. There were no factors associated with the BP lowering effects of PTRA. The baseline resistive index (RI) was negatively correlated with the change in eGFR (). After correction for age, sex, BMI, and the dose of contrast medium, the association of RI with change in eGFR remained significant. Conclusion. In cases with hemodynamically significant RAS, PTRA lowered BP but was not effective in improving renal function. Higher baseline RI may be a factor for predicting poor clinical course of renal function after PTRA.